Clinical Trial Results Published, Conference Calls, Earnings Releases Scheduled, and Royalty Agreements - Research Report on Amgen, Cigna, AstraZeneca, CareFusion, and WellCare

Jan 07, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 7, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Amgen Inc. (NASDAQ: AMGN), Cigna Corporation (NYSE: CI), AstraZeneca plc (NYSE: AZN), CareFusion Corporation (NYSE: CFN), and WellCare Health Plans, Inc. (NYSE: WCG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Amgen Inc. Research Report

On January 1, 2014, Amgen Inc. (Amgen),along with UCB, a Belgium-based global biopharmaceutical company, announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).The Company reported that the phase 2 data has been published in the New England Journal of Medicine (NEJM). According to Amgen, the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD assessment at three months. Amgen added that in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX (alendronate sodium) and FORTEO™/FORSTEO®(teriparatide). Commenting on the results, Michael McClung, M.D., Director of Oregon Osteoporosis Center and Lead Study Investigator, said, "The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment in women with postmenopausal osteoporosis. Additionally, romosozumab treatment resulted in greater increases in bone mineral density than those seen with both placebo and the active comparators. These data provide important insight into this medicine being developed for women with postmenopausal osteoporosis at high risk for fractures." The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e96b_AMGN

Cigna Corporation Research Report

On December 23, 2013, Cigna Corporation (Cigna) announced that the Company will release its Q4 2013 and full-year 2013 financial results on February 7, 2014. Furthermore, the Company reported the schedule of its quarterly earnings releases during the fiscal year 2014. Cigna informed that it will release its Q1 2014 financial results on May 1, 2014; Q2 2014 financial results on July 31, 2014; Q3 2014 financial results on October 30, 2014; and Q4 2014 on February 5, 2015. The Company further informed that its quarterly financial results will be released at approximately 6:30 a.m. ET on the day of the release, while its management will review results on a conference call for investors and financial analysts, starting 8:30 a.m. ET on the same day. The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7307_CI

AstraZeneca plc Research Report

On December 26, 2013, AstraZeneca plc (AstraZeneca) announced full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR sales. According to AstraZeneca, the Company and Shionogi & Co. Ltd. have extended the global license agreement for CRESTOR and also modified the royalty structure, effective January 1, 2014. AstraZeneca informed that under the revised terms of agreement, the structure of royalty payments from AstraZeneca to Shionogi has been modified to reduce the effective royalty rate in 2014-2015, wherein the amount of royalty rate reduction will be a low single-digit number. AstraZeneca further reported that the said agreement will extend the period of royalty payments from 2016 to 2023, in order to guarantee a fixed minimum annual royalty to Shionogi from 2014 until 2020 in the low hundreds of millions of dollars while also providing for maximum royalty payments during the period 2016 to 2020 inclusive. The Full Research Report on AstraZeneca plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/09cc_AZN

CareFusion Corporation Research Report

On December 31, 2013, CareFusion Corporation (CareFusion) announced the completion of its acquisition of the Vital Signs division from GE Healthcare in the U.S., China, and certain other geographies. CareFusion, in connection with this first closing, reported that of the agreed purchase price of $500 million to buy Vital Signs, the Company has paid approximately $470 million to GE Healthcare through cash on hand. CareFusion added that the balance of the purchase price will be paid upon completion of the acquisition of the remaining international operations of Vital Signs, pending regulatory review, and customary closing conditions. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4933_CFN

WellCare Health Plans, Inc. Research Report

On December 31, 2013, WellCare Health Plans, Inc. (WellCare) announced its continued support of the non-profit organization Metropolitan Ministries in 2013, helping in its mission to bring hope to the homeless, and those at risk of becoming homeless, in the Tampa Bay area. The Company reported that in 2013, WellCare and its employees donated 825 pounds of food,approximately $10,000, and volunteered for more than 375 hours. WellCare informed that the Company and Metropolitan Ministries have engaged in public-private collaboration since 2008. The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/be48_WCG

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner